Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Oklo Inc — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while Oklo Inc trades at $35.07 (market cap $6.85B). The key difference: Oklo Inc is far larger — about 4× Nuvation Bio Inc. Class A Common Stock's market cap, and Nuvation Bio Inc. Class A Common Stock is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Oklo Inc for 31 Days on average.
| NUVB | OKLO | |
|---|---|---|
Market Cap | $1.71B | $6.85B |
Volume | 5,448,712 | 11,387,867 |
Sector | Health | Utilities |
52-Week High | $9.54 | $174.14 |
52-Week Low | $3.41 | $34.57 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $1.30B | $4.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OKLO trades at $36.82, down 4.49% on the day, with bearish technical indicators showing resistance at $37-38. The company shows no revenue in 2025 and negative net income of -$105.66M, though analyst consensus remains strongly bullish with a $78.63 price target. Recent news highlights nuclear energy sector momentum but notes OKLO's early commercialization stage and recent $1 billion stock sale.
Outlook hinges on project pipeline execution amid substantial cash burn. High institutional support via financing ($1.26B in 2025) fuels growth bets, but profitability remains distant with a -12,625.54% net margin. Risks include dilution from equity raises and intense SMR competition. The stock offers speculative upside if contracts materialize but carries high volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
